<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00930670</url>
  </required_header>
  <id_info>
    <org_study_id>SPICE</org_study_id>
    <nct_id>NCT00930670</nct_id>
  </id_info>
  <brief_title>Evaluation of the Influence of Statins and Proton Pump Inhibitors on Clopidogrel Antiplatelet Effects</brief_title>
  <acronym>SPICE</acronym>
  <official_title>Evaluation of the Influence of Statins and Proton Pump Inhibitors on Clopidogrel Antiplatelet Effects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is conflicting evidence in the literature suggesting that the use of proton pump
      inhibitors (PPIs), and/or some statins can interfere with clopidogrel antiplatelet effect and
      result in adverse cardiovascular outcomes in patients treated with coronary artery stents and
      dual antiplatelet therapy.

      The primary aim of the study is to determine the effect of various currently used PPI on
      platelet aggregation in patients undergoing percutaneous coronary intervention (PCI) and
      treated with dual antiplatelet therapy.

      The secondary aim of the study is to evaluate how statins and 2C19*2 polymorphism modulate
      the effect of PPI on clopidogrel efficacy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in residual platelet aggregation by light transmittance aggregometry and percent change in platelet reactivity index by VASP</measure>
    <time_frame>At 30 and 60 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Resistance to clopidogrel by light transmittance aggregometry (defined by RPA &gt;55%), resistance to clopidogrel by vasodilator-stimulated phosphoprotein (VASP) (defined by PRI &gt;55%)</measure>
    <time_frame>30 and 60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence and role of CYP 2C19*2 polymorphism on the effect of PPIs and statins on the antiplatelet activity of clopidogrel</measure>
    <time_frame>30 and 60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The composite of death from all causes, myocardial infarction, ischemia-driven repeat revascularization, and stroke</measure>
    <time_frame>30 days, 60 days and 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need to stop any antiplatelet medication for gastrointestinal bleeding or peptic ulcer disease</measure>
    <time_frame>30 days, 60 days and one year</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">320</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Rosuvastatin-omeprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rosuvastatin-omeprazole</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rosuvastatin-pantoprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rosuvastatin 20 mg for 1 month, then rosuvastatin 20 mg and pantoprazole 40 mg for 11 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rosuvastatin-esomeprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rosuvastatin 20 mg for 1 month, then rosuvastatin 20 mg and esomeprazole 40 mg for 11 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rosuvastatin-ranitidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rosuvastatin 20 mg for 1 month, then rosuvastatin 20 mg and ranitidine 300 mg for 11 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin-omeprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and omeprazole 20 mg for 11 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin-pantoprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and pantoprazole 40mg for 11 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin-esomeprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and esomeprazole 40 mg for 11 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin-ranitidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and ranitidine 300mg for 11 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin-omeprazole</intervention_name>
    <description>Rosuvastatin 20 mg for 1 month. Then rosuvastatin 20mg and omeprazole 20mg for 11 months</description>
    <arm_group_label>Rosuvastatin-omeprazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin-pantoprazole</intervention_name>
    <description>Rosuvastatin 20 mg for 1 month, then rosuvastatin 20 mg and pantoprazole 40 mg for 11 months</description>
    <arm_group_label>Rosuvastatin-pantoprazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin-esomeprazole</intervention_name>
    <description>Rosuvastatin 20 mg for 1 month, then rosuvastatin 20 mg and esomeprazole 40 mg for 11 months</description>
    <arm_group_label>Rosuvastatin-esomeprazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin-ranitidine</intervention_name>
    <description>Rosuvastatin 20 mg for 1 month, then rosuvastatin 20 mg and ranitidine 300mg for 11 months</description>
    <arm_group_label>Rosuvastatin-ranitidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin-omeprazole</intervention_name>
    <description>Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and omeprazole 20 mg for 11 months</description>
    <arm_group_label>Atorvastatin-omeprazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin-pantoprazole</intervention_name>
    <description>Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and pantoprazole 40 mg for 11 months</description>
    <arm_group_label>Atorvastatin-pantoprazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin-esomeprazole</intervention_name>
    <description>Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and esomeprazole 40 mg for 11 months</description>
    <arm_group_label>Atorvastatin-esomeprazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin-ranitidine</intervention_name>
    <description>Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and ranitidine 300mg for 11 months</description>
    <arm_group_label>Atorvastatin-ranitidine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must be 18 years of age or older

          -  Bare metal stent implantation

          -  Discharged with dual antiplatelet therapy for at least 60 days

          -  Written informed consent

        Exclusion Criteria:

          -  Patients who do not consent to participate in the study

          -  Premenopausal women not using contraceptive methods or without a negative pregnancy
             test in the past week

          -  Patients treated or planned to be treated with oral anticoagulants

          -  Present treatment with or clear indication for treatment with a PPI or H2 antagonists

          -  Allergy or intolerance to study medications including ranitidine, Proton pump
             inhibitors, atorvastatin, rosuvastatin, aspirin and/or clopidogrel

          -  Patient treated with a strong CYP2C19 interacting drug

          -  History of a bleeding diathesis, or evidence of active abnormal bleeding within 30
             days before enrollment

          -  History of intracranial hemorrhage or intracranial surgery in the last 3 months

          -  History of gastro-intestinal ulcers in the last 3 months

          -  Any serious illness or any condition that the investigator feels would influence the
             impact of this therapy on the subject

          -  Known platelet count &lt; 100000/mm3 at time of enrollment or within 24 hours prior to
             enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Pierre Dery, MD, MHS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Universitaire de Cardiologie et de Pneumologie de Quebec</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1V4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.criucpq.ulaval.ca</url>
    <description>Centre de recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec</description>
  </link>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2009</study_first_submitted>
  <study_first_submitted_qc>June 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2009</study_first_posted>
  <last_update_submitted>February 8, 2012</last_update_submitted>
  <last_update_submitted_qc>February 8, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec</investigator_affiliation>
    <investigator_full_name>Jean-Pierre Dery, MD, MSc</investigator_full_name>
    <investigator_title>Interventional Cardiologist</investigator_title>
  </responsible_party>
  <keyword>ranitidine</keyword>
  <keyword>pantoprazole</keyword>
  <keyword>esomeprazole</keyword>
  <keyword>omeprazole</keyword>
  <keyword>atorvastatin</keyword>
  <keyword>rosuvastatin</keyword>
  <keyword>statin</keyword>
  <keyword>clopidogrel resistance</keyword>
  <keyword>antiplatelet therapy</keyword>
  <keyword>coronary artery disease</keyword>
  <keyword>percutaneous coronary intervention</keyword>
  <keyword>stent</keyword>
  <keyword>clopidogrel</keyword>
  <keyword>proton pump inhibitors</keyword>
  <keyword>drug interactions</keyword>
  <keyword>drug resistance</keyword>
  <keyword>genetic polymorphism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Omeprazole</mesh_term>
    <mesh_term>Esomeprazole</mesh_term>
    <mesh_term>Pantoprazole</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ranitidine</mesh_term>
    <mesh_term>Ranitidine bismuth citrate</mesh_term>
    <mesh_term>Proton Pump Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

